Just as most businesses in China started to put COVID-19 behind them after over 50 days without domestically transmitted cases, the reemergence over the weekend in Beijing, capital city of China, has increased uncertainty on the epidemic. This spurs an urgent need for antiviral drug discovery.

With years of experience in antiviral drug development, Creative Biolabs has combined with integrated, multidisciplinary drug discovery expertise and unparalleled scope of capabilities in SARS-CoV-2 candidatesscreening, effective viral inhibitors discovery, therapeutic antibody development and vaccine exploration. Specifically, the newly updated broad-spectrum SARS-CoV-2 antiviral drug discovery services are ready to move forward and speed up related research.

Creative Biolabs provides discovery services of SARS-CoV-2 broad-spectrum antiviral drug, in which mechanisms drugs with broad-spectrum SARS-CoV-2 antiviral activities mainly involve inhibiting or killing the virus directly, interference with virus attachment/membrane fusion, preventing the virus from penetrating into cells, enhancing the antiviral ability of the host, etc.

In these mechanisms of antiviral infection, the enhancement of host cellular defense, as the first barrier, is of great significance. Hence, interferons (IFNs), especially IFN-alpha and IFN-beta produced by infected cells, not only show antiviral activities but also induce various kinds of biological/immunological activities, exerting an antiviral or anti-SARS-CoV-2 role in several aspects.

IFN-alpha is a subtype of type I IFN produced by infected leukocytes exhibiting a diversity of biological activities. IFN-alphas exhibit great potential in the prevention and treatment of SARS-CoV-2 infection, since that it not only interferes with virus replication of infected cells before acquired immunity, but also activates multiple pathways to fight against SARS-CoV-2. Aiming to human health improvement, Creative Biolabs provides comprehensive SARS-CoV-2-related IFN-alpha products and drug development services.

IFN-β, a kind of type I interferon produced by fibroblast and plasmacytoid dendritic cells in mammals, also exhibits great antiviral activity and anti-proliferative and immune-regulation effects. The recombinant human IFN-β1a has been confirmed to effectively inhibit the replication of severe acute respiratory syndrome (SARS) virus, thus IFN-β stands a good chance of being a candidate for the treatment of SARS-CoV-2 infections. Broad-spectrum SARS-CoV-2 antiviral drug discovery services of Creative Biolabs also cover related research on IFN-β.

“We have comprehensive and advanced technology platforms and our scientist team are specialized in viral immunity with abundant experience in antiviral drug discovery in SARS-CoV and MERS-CoV.” Said the business manager of Creative Biolabs, “we are highly concerned about the novel coronavirus infection and are ready to help advance the related research.”

Creative Biolabs has rapidly integrated all-round resources and existing research results on SARS-CoV-2. Apart from the aforementioned services, Creative Biolabs also provides high-throughput screening of novel drug candidates, inhibitors discovery, neutralizing antibody development, antiviral peptide discovery, etc. More information can be found on https://sars-cov-2.creative-biolabs.com.

About Creative Biolabs

Empowered by leading technology and over 15 years of experience in biomedical science, Creative Biolabs has successfully accomplished numerous challenging projects for customers in requirements. Especially in the field of antiviral drugs and vaccines, Creative Biolabs provides drug discovery, vaccine design, preclinical evaluation of drugs and vaccines, and in vitro diagnostic services at the world-leading level.